IL2 and neoplasm: In advanced-stage (stage IV, AJCC, American Joint Committee on Cancer) melanoma patients, clinical trials using TIL combined with interleukin-2 (IL-2) have shown a response rate of 35% [3]–[4], and more recently, while using rapidly expanded tumor infiltrating lymphocyte cultures and high-dose IL-2 therapy after lymphodepleting conditioning, authors reported a 51% rate of objective clinical responses [5].